GlycoEra’s lead candidate targets IgG4 autoantibodies, potentially addressing autoimmune diseases such as muscle-specific kinase myasthenia gravis and pemphigus.
Novo-Backed GlycoEra Raises $130M To Advance Protein Degraders for Precision Immunology